News Release

 

Back
 

AmerisourceBergen Reports Record Operating Revenue and Cash Flow in Year-End Results; Company Expects Diluted Earnings Per Share of $3.95 to $4.25 for Fiscal 2006

11/03/05

VALLEY FORGE, Pa., Nov 03, 2005 (BUSINESS WIRE) -- AmerisourceBergen Corporation (NYSE:ABC) today reported results for its fiscal fourth quarter and year ended September 30, 2005. The following results are presented in accordance with U.S. generally accepted accounting principles (GAAP).

Fiscal Fourth Quarter Highlights

-- Diluted earnings per share from continuing operations of $0.20, including special charges of $0.75 related primarily to early debt retirement.

-- Record operating revenue of $13.0 billion, up 7 percent.

-- Record low interest expense of $9.4 million.

-- Low total debt to total capital ratio of 18.2 percent.

Fiscal Year Highlights

-- Diluted earnings per share from continuing operations of $2.73 before the cumulative effect of an accounting change, including net special charges of $0.60.

-- Record operating revenue of $50.0 billion, up 2 percent.

-- Record cash flow from operations of $1.53 billion.

"In the fiscal fourth quarter, excluding special charges, we delivered strong operating performance that represents positive momentum as we exit a challenging year and begin a promising fiscal 2006," said R. David Yost, AmerisourceBergen's Chief Executive Officer. "Our disciplined working capital management and timely refinancing has produced the strongest balance sheet in our history. The transition to a fee-for-service model with our branded pharmaceutical manufacturers is largely complete. We are enthusiastic about our future with increasing business opportunities including our recent entry into the Canadian market, completion of our new distribution network, continued expansion of generic usage, continuation of our specialty business's strong growth and our ability to leverage over time the added pharmaceutical utilization of the Medicare Modernization Act which begins in January 2006."

Discussion of Results

AmerisourceBergen's operating revenue was a record $13.0 billion in the fourth quarter of fiscal 2005 compared to $12.1 billion for the same period last year, a 7 percent increase. Bulk deliveries in the quarter decreased 23 percent to $953.5 million.

Consolidated operating income in the September quarter declined 11 percent to $155.0 million compared to the prior year's fourth quarter. A $12.0 million charge for facility consolidation and employee severance, most of which was for the outsourcing of information technology activities, negatively impacted operating income. An anticipated gain from an antitrust settlement was not received until October and will benefit operating income by approximately $15 million in the first quarter of fiscal 2006, although the gain is expected to be offset by facility consolidation and employee severance costs. In the September quarter of 2004, the facility consolidation and employee severance charge was $2.2 million.

During the fourth fiscal quarter, the Company successfully tendered for and retired its $500 million, 8.125 percent bonds due 2008 and its $300 million, 7.25 percent bonds due 2012, replacing them with two new bonds, a $400 million, seven-year bond with an effective rate of 5.71 percent and a 10-year, $500 million bond with an effective rate of 5.94 percent.

Interest expense in the fourth quarter of fiscal 2005 was a record low $9.4 million compared to $23.5 million in the prior year's fourth quarter, a 60 percent decrease driven by net debt reduction.

The effective tax rate for the fourth quarter of fiscal 2005 was 38.3 percent compared to 38.0 percent in the same quarter of the previous year. The tax rate applied to the early retirement of debt in fiscal 2005's fourth quarter was 36.1 percent as its costs are not deductible in certain states.

Diluted earnings per share from continuing operations for the fourth quarter of fiscal 2005 were $0.20 compared to $0.82 in the prior year's fourth quarter. Included in the fiscal 2005 fourth quarter results is a charge of $0.68 per diluted share, net of tax, related to the retirement of debt and a $0.07 per diluted share, net of tax, charge for facility consolidation and employee severance costs. The previous fiscal year's fourth quarter included a facility consolidation and employee severance charge of $0.01 per diluted share, net of tax.

Weighted average diluted shares outstanding for the fourth quarter of fiscal year 2005 were 104.8 million, a reduction from 117.0 million in the same period last year primarily due to the Company's share repurchase programs during the year.

Operating revenue in fiscal year 2005 increased 2 percent to a record $50.0 billion from $48.8 billion in the previous fiscal year. Bulk deliveries to customer warehouses were up 6 percent to $4.6 billion.

Consolidated operating income for fiscal 2005 decreased 29 percent to $636.9 million as gross profit declined and operating expenses increased for the fiscal year.

For the fiscal year ended September 30, 2005, diluted earnings per share from continuing operations were $2.73 before the cumulative effect of a change in accounting and included a net charge of $0.60, net of tax, for special items, which were primarily the costs related to the early retirement of debt, facility consolidations and employee severance and the gains from litigation settlements. Diluted earnings per share from continuing operations in fiscal 2004 were $4.12, which included a net benefit of $0.04 related to gains from litigation settlements, net the costs related to the early retirement of debt, facility consolidations and employee severance.

Cash generated from operations in fiscal 2005 was $1.53 billion compared to $825 million last fiscal year. The Company's total debt to total capital ratio was a low 18.2 percent.

"In the fourth quarter of fiscal 2005, the strong operating performance in pharmaceutical distribution overcame performance in PharMerica that was below our expectations," said Kurt J. Hilzinger, AmerisourceBergen's President and Chief Operating Officer.

"AmerisourceBergen Specialty Group continued to be a growth driver with annual operating revenue of more than $7 billion. Led by its market-leading oncology business, with strong performances in the plasma and reimbursement consulting businesses, the Group delivered outstanding growth in the quarter.

"In the Drug Corporation, our customer-focused Transform program continued to gain momentum in the quarter, and our generics program also was a significant contributor. Our Optimiz(R) program, which is designed to lower our operating costs, continued on schedule and on budget. In fiscal 2005, we opened new state-of-the-art facilities in Columbus, Dallas, and Chicago, and we consolidated six distribution centers for a total of 32 in the U.S. at the end of the fiscal year. In fiscal 2006, we opened our new Kansas City distribution center in October, 2005 and expect to open the final of our six new facilities in Bethlehem, Pennsylvania, in the spring. We expect to consolidate six facilities in fiscal 2006, bringing the number of distribution centers in our U.S. network to 28, and expect the total number of U.S. distribution centers to be in the mid-twenties by the end of fiscal 2007."

"In the fourth quarter, our PharMerica segment continued to face a difficult and competitive long-term care environment, especially around market pricing and government reimbursement. Although the market is beginning to present some opportunities with completion of the merger between the two other national long-term care institutional pharmacy companies, the challenges remaining in the move to Medicare Part D will make 2006 a transition year for PharMerica. Our expectation in fiscal 2006 is for mid single-digit revenue growth and slightly lower operating margins," said Hilzinger.

Segment Review

AmerisourceBergen operates in two segments: Pharmaceutical Distribution (which includes the operations of AmerisourceBergen Drug Corporation and the AmerisourceBergen Specialty, Packaging and Technology groups) and PharMerica (which includes the long-term care pharmacy and workers' compensation fulfillment businesses). Intersegment sales of $219.5 million in the fourth quarter of fiscal 2005 from AmerisourceBergen Drug Corporation to PharMerica, which are included in the Pharmaceutical Distribution segment operating revenue, are eliminated for consolidated reporting purposes.

Pharmaceutical Distribution Segment

Operating revenue in the fourth quarter of fiscal 2005 increased to a record $12.8 billion compared with $12.0 billion in the fourth quarter of fiscal year 2004, a 7 percent increase.

Pharmaceutical Distribution customer mix in the fourth quarter of fiscal 2005 was 59 percent institutional and 41 percent retail, reflecting strong growth in the Specialty Group.

For the segment, gross profit as a percentage of operating revenue in the fourth quarter of fiscal 2005 was 3.20 percent, compared to 3.12 percent in the same period in the prior fiscal year. Operating income as a percentage of operating revenue was 1.18 percent in the September quarter of fiscal 2005 compared with 1.20 percent in the prior fiscal year's September quarter. The Company recorded a LIFO credit of $15.0 million in the quarter, compared to a $27.4 million credit in the same quarter of the prior year, due to the significant reduction in inventory during the year. The positive impact of the credit was offset by losses from hurricanes Katrina and Rita as well as higher than average bad debt expense.

PharMerica

PharMerica's operating revenue for the fourth quarter of fiscal 2005 was $401.6 million, a 3 percent increase over the previous year's fourth quarter. Operating income for the same period was $15.9 million, compared to $33.8 million for the same quarter last year, which was favorably impacted by a $12 million reduction in sales and use tax expense.

Looking To Fiscal 2006

"For fiscal 2006, we expect diluted earnings per share to be between $3.95 and $4.25 and operating revenue growth to be in the range of 6 percent to 8 percent," said Yost. "Our earnings per share expectations include the impact of a $0.09 charge for equity compensation expense and the anticipation that litigation recovery gains will be offset by facility consolidation and employee severance expense. In the pharmaceutical distribution segment, we expect operating margins for fiscal 2006 to be in the range of 115 to 125 basis points. Cash flow from operations in fiscal 2006 is expected to be in the range of $500 million to $600 million."

Conference Call

The Company will host a conference call to discuss its results at 11:00 a.m. Eastern Standard Time on November 3, 2005. Participating in the conference call will be: R. David Yost, Chief Executive Officer; Kurt J. Hilzinger, President and Chief Operating Officer; and Michael D. DiCandilo, Executive Vice President and Chief Financial Officer.

To access the live conference call via telephone:

Dial in: (612) 326-1011, no access code required.

To access the live webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at
http://www.amerisourcebergen.com.

A replay of the telephone call and webcast will be available from 3:00
p.m. November 4, 2005 until 11:59 p.m. November 10, 2005. The Webcast
replay will be available for 30 days.

To access the replay via telephone:

Dial in: (800) 475-6701 from within the U.S., access code: 799257
         (320) 365-3844 from outside the U.S., access code: 799257

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at
http://www.amerisourcebergen.com.

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is one of the largest pharmaceutical services companies in the United States. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to pharmacy services for skilled nursing and assisted living facilities, reimbursement and pharmaceutical consulting services, and physician education. With more than $54 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 14,000 people. AmerisourceBergen is ranked #23 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

This news release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. Forward-looking statements may include statements addressing AmerisourceBergen's future financial and operating results and the benefits, efficiencies and savings to be derived from the Company's integration plans to consolidate its distribution network.

The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer or supplier relationships; customer defaults or insolvencies; changes in customer mix; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other disputes with customers (including departments and agencies of the U.S. Government) or suppliers; regulatory changes; changes in U.S. government policies (including reimbursement changes arising from the Medicare Modernization Act); market interest rates; operational or control issues arising from AmerisourceBergen's outsourcing of information technology activities; success of the Pharmaceutical Distribution segment's ability to transition its business model to fee-for-service; success of integration, restructuring or systems initiatives; fluctuations in the U.S. dollar - Canadian dollar exchange rate; economic, business, competitive and/or regulatory developments in Canada; acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; and other economic, business, competitive, legal, regulatory and/or operational factors affecting the business of AmerisourceBergen generally.

More detailed information about these and other risk factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2004.

AmerisourceBergen is under no obligation to (and expressly disclaims any such obligation to) update or alter any forward looking statements whether as a result of new information, future events or otherwise.

AMERISOURCEBERGEN CORPORATION
                          FINANCIAL SUMMARY
                (In thousands, except per share data)
                             (unaudited)



                     Three                  Three
                  Months Ended   % of    Months Ended   % of
                   September   Operating  September   Operating   %
                    30, 2005    Revenue    30, 2004    Revenue  Change
                  ------------ --------- ------------ --------- ------

Revenue:
  Operating
   revenue        $12,964,857    100.00% $12,130,843    100.00%     7%
  Bulk deliveries
   to customer
   warehouses         953,496              1,243,388              -23%
                  ------------           ------------
Total revenue      13,918,353             13,374,231                4%

Cost of goods
 sold              13,396,579             12,883,536                4%
                  ------------           ------------

Gross profit          521,774      4.02%     490,695      4.05%     6%

Operating
 expenses:
  Distribution,
   selling and
   administrative     333,874      2.58%     294,046      2.42%    14%
  Depreciation
   and
   amortization        20,896      0.16%      19,812      0.16%     5%
  Facility
   consolidations,
   employee
   severance, and
   other               12,006      0.09%       2,198      0.02%   446%
                  ------------           ------------

Operating income      154,998      1.20%     174,639      1.44%   -11%

Other loss
 (income)                 160      0.00%        (251)     0.00%   N/A

Interest expense,
 net                    9,355      0.07%      23,482      0.19%   -60%
Loss on early
 retirement of
 debt                 110,873      0.86%           -      0.00%   N/A
                  ------------           ------------

Income from
 continuing
 operations
 before taxes          34,610      0.27%     151,408      1.25%   -77%

Income taxes           13,268      0.10%      57,521      0.47%   -77%
                  ------------           ------------

Income from
 continuing
 operations            21,342      0.16%      93,887      0.77%   -77%

Loss from
 discontinued
 operations, net
 of taxes               1,842                  1,898
                  ------------           ------------

Net income            $19,500      0.15%     $91,989      0.76%   -79%
                  ============           ============


Earnings per
 share:
  Basic
    Continuing
     operations         $0.21                  $0.85              -75%
    Discontinued
     operations         (0.02)                 (0.02)
                  ------------           ------------
      Net income        $0.19                  $0.83              -77%
                  ============           ============

  Diluted
    Continuing
     operations         $0.20                  $0.82              -76%
    Discontinued
     operations         (0.02)                 (0.02)
    Rounding             0.01                   0.01
                  ------------           ------------
      Net income        $0.19                  $0.81              -77%
                  ============           ============

Weighted average
 common shares
 outstanding:
  Basic               103,753                110,962
  Diluted             104,848                116,991


                    AMERISOURCEBERGEN CORPORATION
                          FINANCIAL SUMMARY
                (In thousands, except per share data)
                             (unaudited)


                     Fiscal                 Fiscal
                   Year Ended    % of     Year Ended    % of
                   September   Operating  September   Operating   %
                    30, 2005    Revenue    30, 2004    Revenue  Change
                  ------------ --------- ------------ --------- ------

Revenue:
  Operating
   revenue        $50,012,598    100.00% $48,812,452    100.00%     2%
  Bulk deliveries
   to customer
   warehouses       4,564,723              4,308,339                6%
                  ------------           ------------
Total revenue      54,577,321             53,120,791                3%

Cost of goods
 sold              52,597,137             50,954,361                3%
                  ------------           ------------

Gross profit        1,980,184      3.96%   2,166,430      4.44%    -9%

Operating
 expenses:
  Distribution,
   selling and
   administrative   1,234,057      2.47%   1,184,529      2.43%     4%
  Depreciation
   and
   amortization        81,199      0.16%      73,425      0.15%    11%
  Facility
   consolidations,
   employee
   severance, and
   other               22,723      0.05%       7,517      0.02%   202%
  Impairment
   charge               5,259      0.01%           -      0.00%   N/A
                  ------------           ------------

Operating income      636,946      1.27%     900,959      1.85%   -29%

Other income             (990)     0.00%      (6,236)    -0.01%   N/A

Interest expense,
 net                   57,223      0.11%     112,704      0.23%   -49%
Loss on early
 retirement of
 debt                 111,888      0.22%      23,592      0.05%   N/A
                  ------------           ------------

Income before
 taxes,
 discontinued
 operations, and
 cumulative
 effect of change
 in accounting        468,825      0.94%     770,899      1.58%   -39%

Income taxes          176,903      0.35%     296,025      0.61%   -40%
                  ------------           ------------

Income from
 continuing
 operations
 before
 cumulative
 effect of change
 in accounting        291,922      0.58%     474,874      0.97%   -39%

Loss from
 discontinued
 operations, net
 of taxes              17,105                  6,484
Cumulative effect
 of change in
 accounting, net
 of taxes              10,172                      -
                  ------------           ------------

Net income           $264,645      0.53%    $468,390      0.96%   -43%
                  ============           ============


Earnings per
 share:
  Basic
    Continuing
     operations         $2.76                  $4.25              -35%
    Discontinued
     operations         (0.16)                 (0.06)
    Cumulative
     effect of
     change in
     accounting         (0.10)                     -
    Rounding                -                   0.01
                  ------------           ------------
      Net income        $2.50                  $4.20              -40%
                  ============           ============

  Diluted
    Continuing
     operations         $2.73                  $4.12              -34%
    Discontinued
     operations         (0.16)                 (0.06)
    Cumulative
     effect of
     change in
     accounting         (0.09)                     -
                  ------------           ------------
      Net income        $2.48                  $4.06              -39%
                  ============           ============

Weighted average
 common shares
 outstanding:
  Basic               105,667                111,617
  Diluted             107,770                117,779


                     AMERISOURCEBERGEN CORPORATION
                 CONDENSED CONSOLIDATED BALANCE SHEETS
                            (in thousands)
                             (unaudited)


                 ASSETS
                                          September 30,  September 30,
                                              2005           2004
                                          -------------  -------------
Current assets:
  Cash and cash equivalents                 $1,315,683       $871,343
  Accounts receivable, net                   2,640,646      2,260,973
  Merchandise inventories                    4,003,690      5,135,830
  Prepaid expenses and other                    27,673         27,243
                                          -------------  -------------
    Total current assets                     7,987,692      8,295,389

Long-term assets                             3,393,482      3,358,614
                                          -------------  -------------

    Total assets                           $11,381,174    $11,654,003
                                          =============  =============


  LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                          $5,292,253     $4,947,037
  Current portion of long-term debt              1,232        281,360
  Other current liabilities                    758,611        875,511
                                          -------------  -------------
    Total  current  liabilities              6,052,096      6,103,908

Long-term debt, less current portion           951,479      1,157,111

Other liabilities                               97,242         53,939

Stockholders' equity                         4,280,357      4,339,045
                                          -------------  -------------

  Total liabilities and stockholders'
   equity                                  $11,381,174    $11,654,003
                                          =============  =============


                    AMERISOURCEBERGEN CORPORATION
           CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                            (in thousands)
                             (unaudited)


                                             Fiscal         Fiscal
                                           Year Ended     Year Ended
                                          September 30,  September 30,
                                              2005           2004
                                          -------------  -------------

Operating Activities:
  Net income                                  $264,645       $468,390
  Changes in operating assets and
   liabilities                                 976,688        205,231
  Adjustments to reconcile net income to
   net cash provided by operating
   activities                                  285,305        151,460
                                          -------------  -------------
Net cash provided by operating activities    1,526,638        825,081
                                          -------------  -------------

Investing Activities:
  Capital expenditures                        (203,376)      (189,278)
  Cost of acquired companies, net of cash
   acquired and other                           (4,404)       (68,882)
  Proceeds from sale-leaseback
   transactions                                 36,696         15,602
  Proceeds from sales of discontinued
   operations                                   14,560              -
  Proceeds from sales of property and
   equipment                                     4,219            336
                                          -------------  -------------
Net cash used in investing activities         (152,305)      (242,222)
                                          -------------  -------------

Financing Activities:
  Long-term debt borrowings                    895,500              -
  Long-term debt repayments                 (1,182,339)      (368,425)
  Exercise of stock options                    174,063         15,151
  Cash dividends on common stock               (10,598)       (11,197)
  Purchases of common stock                   (786,192)      (144,756)
  Deferred financing costs and other           (20,427)        (2,325)
                                          -------------  -------------
Net cash used in financing activities         (929,993)      (511,552)
                                          -------------  -------------

Increase in cash and cash equivalents          444,340         71,307

Cash and cash equivalents at beginning of
 period                                        871,343        800,036
                                          -------------  -------------

Cash and cash equivalents at end of
 period                                     $1,315,683       $871,343
                                          =============  =============


                    AMERISOURCEBERGEN CORPORATION
                     SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                             (unaudited)


                                    Three Months Ended September 30,
                                   -----------------------------------
Operating Revenue                     2005         2004      % Change
---------------------------------- -----------------------------------

Pharmaceutical Distribution        $12,782,748  $11,966,119         7%
PharMerica                             401,627      390,405         3%
Intersegment eliminations             (219,518)    (225,681)        3%
                                   ------------ ------------

  Operating revenue                $12,964,857  $12,130,843         7%
                                   ============ ============


                                    Three Months Ended September 30,
                                   -----------------------------------
Operating Income                      2005         2004      % Change
---------------------------------- -----------------------------------

Pharmaceutical Distribution           $151,151     $143,071         6%
PharMerica                              15,853       33,766       -53%
Facility consolidations, employee
 severance, and other                  (12,006)      (2,198)     -446%
                                   ------------ ------------

  Operating income                    $154,998     $174,639       -11%
                                   ============ ============


Percentages of operating revenue:

Pharmaceutical Distribution
  Gross profit                            3.20%        3.12%
  Operating expenses                      2.02%        1.93%
  Operating income                        1.18%        1.20%

PharMerica
  Gross profit                           27.98%       30.02%
  Operating expenses                     24.03%       21.37%
  Operating income                        3.95%        8.65%

AmerisourceBergen Corporation
  Gross profit                            4.02%        4.05%
  Operating expenses                      2.83%        2.61%
  Operating income                        1.20%        1.44%


                    AMERISOURCEBERGEN CORPORATION
                     SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                             (unaudited)


                                     Fiscal Year Ended September 30,
                                   -----------------------------------
Operating Revenue                     2005         2004      % Change
---------------------------------- -----------------------------------

Pharmaceutical Distribution        $49,319,371  $48,113,015         3%
PharMerica                           1,571,369    1,575,255         0%
Intersegment eliminations             (878,142)    (875,818)        0%
                                   ------------ ------------

  Operating revenue                $50,012,598  $48,812,452         2%
                                   ============ ============


                                     Fiscal Year Ended September 30,
                                   -----------------------------------
Operating Income                      2005         2004      % Change
---------------------------------- -----------------------------------

Pharmaceutical Distribution           $532,887     $748,625       -29%
PharMerica                              91,947      121,846       -25%
Facility consolidations, employee
 severance, and other                  (22,723)      (7,517)     -202%
Gain on litigation settlements          40,094       38,005         5%
Impairment charge                       (5,259)           -       N/A
                                   ------------ ------------

  Operating income                    $636,946     $900,959       -29%
                                   ============ ============


Percentages of operating revenue:

Pharmaceutical Distribution
  Gross profit                            3.03%        3.43%
  Operating expenses                      1.95%        1.87%
  Operating income                        1.08%        1.56%

PharMerica
  Gross profit                           28.40%       30.45%
  Operating expenses                     22.54%       22.72%
  Operating income                        5.85%        7.74%

AmerisourceBergen Corporation
  Gross profit                            3.96%        4.44%
  Operating expenses                      2.69%        2.59%
  Operating income                        1.27%        1.85%


                     AMERISOURCEBERGEN CORPORATION
                          EARNINGS PER SHARE
                (In thousands, except per share data)
                             (unaudited)


Basic earnings per share is computed on the basis of the weighted
average number of shares of common stock outstanding during the
periods presented. Diluted earnings per share is computed on the basis
of the weighted average number of shares of common stock outstanding
during the period plus the dilutive effect of stock options.
Additionally, the diluted earnings per share calculation considers the
convertible subordinated notes as if converted and, therefore, the
effect of interest expense related to those notes is added back to net
income in determining income from continuing operations available to
common stockholders.


                               Three Months Ended   Fiscal Year Ended
                                  September 30,       September 30,
                                 2005      2004      2005      2004
                               --------- --------- --------- ---------

Income from continuing
 operations, before cumulative
 effect of change in
 accounting                     $21,342   $93,887  $291,922  $474,874
Interest expense - convertible
 subordinated notes, net of
 income taxes                         -     2,551     2,539    10,141
                               --------- --------- --------- ---------
Income from continuing
 operations available to
 common stockholders            $21,342   $96,438  $294,461  $485,015
                               ========= ========= ========= =========

Weighted average common shares
 outstanding - basic            103,753   110,962   105,667   111,617
Effect of dilutive securities:
   Options to purchase common
    stock                         1,095       365       658       498
   Convertible subordinated
    notes                             -     5,664     1,445     5,664
                               --------- --------- --------- ---------

Weighted average common shares
 outstanding - diluted          104,848   116,991   107,770   117,779
                               ========= ========= ========= =========


Earnings per share:
   Basic
      Continuing operations       $0.21     $0.85     $2.76     $4.25
      Discontinued operations     (0.02)    (0.02)    (0.16)    (0.06)
      Cumulative effect of
       change in accounting           -         -     (0.10)        -
      Rounding                        -         -         -      0.01
                               --------- --------- --------- ---------
         Net income               $0.19     $0.83     $2.50     $4.20
                               ========= ========= ========= =========

   Diluted
      Continuing operations       $0.20     $0.82     $2.73     $4.12
      Discontinued operations     (0.02)    (0.02)    (0.16)    (0.06)
      Cumulative effect of
       change in accounting           -         -     (0.09)        -
      Rounding                     0.01      0.01         -         -
                               --------- --------- --------- ---------
         Net income               $0.19     $0.81     $2.48     $4.06
                               ========= ========= ========= =========


                    AMERISOURCEBERGEN CORPORATION
                         CHANGE IN ACCOUNTING
                             (UNAUDITED)


Effective October 1, 2004, the Company changed its method of
recognizing cash discounts and other related manufacturer incentives.
The Company previously recognized cash discounts as a reduction of
cost of goods sold when earned, which was primarily upon payment of
vendor invoices. The Company now records cash discounts as a component
of inventory cost and recognizes such discounts as a reduction to cost
of goods sold upon the sale of the inventory. In connection with the
Company's transition to a fee-for-service model, the Company believes
the change in accounting method provides a more objectively
determinable method of recognizing cash discounts and a better
matching of inventory cost to revenue, as inventory turnover rates are
expected to continue to improve.

The Company recorded a $10.2 million cumulative effect of change in
accounting (net of tax of $6.3 million) in the consolidated statement
of operations for the fiscal year ended September 30, 2005. This $10.2
million cumulative effect adjustment reduced diluted earnings per
share by $0.09 for the fiscal year ended September 30, 2005. The
accounting change is incorporated in the Company's results for the
three months ended September 30, 2005, and the change decreased
earnings from continuing operations in the September quarter by
approximately $0.5 million, net of tax, and had no impact on diluted
earnings per share from continuing operations. The accounting change
improved earnings from continuing operations in the fiscal year ended
September 30, 2005 by approximately $11.5 million, net of tax, or
$0.11 per diluted share from continuing operations.


The pro forma effect of this accounting change on prior periods is as
follows:

                                          Three Months    Fiscal Year
                                              Ended          Ended
(in thousands, except per share data)     September 30,  September 30,
                                              2004           2004
----------------------------------------- -------------  -------------

Income from continuing operations before
 cumulative effect of change in accounting:
   As Reported                                 $93,887       $474,874
   Pro Forma                                   $91,879       $472,653
Net income:
   As Reported                                 $91,989       $468,390
   Pro Forma                                   $89,981       $466,169

Basic earnings per share from continuing
 operations:
   As Reported                                   $0.85          $4.25
   Pro Forma                                     $0.83          $4.23

Diluted earnings per share from
 continuing operations:
   As Reported                                   $0.82          $4.12
   Pro Forma                                     $0.81          $4.10

SOURCE: AmerisourceBergen Corporation

AmerisourceBergen Corporation, Valley Forge
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More